© 2023 MJH Life Sciences™ and Drug Topics. All rights reserved.
FDA has approved Boston Therapeutic’s petition to file an Abbreviated New Drug Application (ANDA) for a new, chewable tablet formulation of the diabetes drug metformin hydrochloride. The company plans to market the new formulation under the name Pazamet.